4//SEC Filing
AVADEL PHARMACEUTICALS PLC 4
Accession 0001144204-17-000118
$AVDLCIK 0001012477operating
Filed
Jan 2, 7:00 PM ET
Accepted
Jan 3, 2:12 PM ET
Size
11.0 KB
Accession
0001144204-17-000118
Insider Transaction Report
Form 4
NAVARRE CHRISTOPHE
Director
Transactions
- Disposition to Issuer
Warrants (right to buy)
2016-12-31−46,000→ 0 totalExercise: $14.54From: 2015-06-24Exp: 2018-06-24→ ADSs (46,000 underlying) - Disposition to Issuer
Warrants (right to buy)
2016-12-31−54,026→ 0 totalExercise: $21.67From: 2016-06-26Exp: 2019-06-26→ ADSs (54,026 underlying)
Footnotes (5)
- [F1]Warrants were granted 06/24/2014 but were not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants became exercisable for a 3-year period as to all 46,000 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)10.94 per ADS.
- [F2]On 12/31/16, Flamel Technologies S.A. ("Flamel") merged with and into Avadel Pharmaceuticals plc ("Avadel"). As a result of the Merger, Flamel's outstanding ordinary shares were cancelled and exchanged on a 1-for-1 basis for newly issued ordinary shares of Avadel, and all outstanding American Depositary Shares (ADSs) representing Flamel ordinary shares were cancelled and exchanged on a 1-for-1 basis for ADSs representing Avadel ordinary shares. The reporting person is filing this Form 4 solely to report dispositions of Flamel securities as a result of the Merger. The reporting person will also file a Form 3 to reflect his or her new status as a director and/or executive officer of Avadel, and a new Form 4 evidencing his or her acquisition of the same number and type of securities of Avadel in the Merger. The reporting person made no market sales or purchases in connection with the dispositions reported in this Form 4 or the acquisitions to be reported in the new Form 4.
- [F3]The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value 0.122 Euros per share, of the issuer; ADSs are represented by American Depositary Receipts.
- [F4]Flamel Ordinary Shares and Flamel ADSs were exchanged in the Merger for an equal number of Avadel Ordinary Shares and Avadel ADSs (as applicable), respectively.
- [F5]Warrants were granted 06/26/2015 but are not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants will become exercisable for a 3-year period as to all 54,026 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)19.34 per ADS. Warrants as to all 54,026 ADSs vest on 06/26/2016.
Documents
Issuer
AVADEL PHARMACEUTICALS PLC
CIK 0001012477
Entity typeoperating
Related Parties
1- filerCIK 0001012477
Filing Metadata
- Form type
- 4
- Filed
- Jan 2, 7:00 PM ET
- Accepted
- Jan 3, 2:12 PM ET
- Size
- 11.0 KB